Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

James, Stefan ; Angiolillo, Dominick J. ; Cornel, Jan H. ; Erlinge, David LU orcid ; Husted, Steen ; Kontny, Frederic ; Maya, Juan ; Nicolau, Jose C. ; Spinar, Jindrich and Storey, Robert F. , et al. (2010) In European Heart Journal 31(24). p.3006-3016
Abstract
Patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events and bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but with similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control. We analysed patients with pre-existing DM (n = 4662), including 1036 patients on insulin, those without DM (n = 13 951), and subgroups based on admission levels of haemoglobin A1c (HbA1c; n = 15 150). In patients with DM, the... (More)
Patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events and bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but with similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control. We analysed patients with pre-existing DM (n = 4662), including 1036 patients on insulin, those without DM (n = 13 951), and subgroups based on admission levels of haemoglobin A1c (HbA1c; n = 15 150). In patients with DM, the reduction in the primary composite endpoint (HR: 0.88, 95% CI: 0.76-1.03), all-cause mortality (HR: 0.82, 95% CI: 0.66-1.01), and stent thrombosis (HR: 0.65, 95% CI: 0.36-1.17) with no increase in major bleeding (HR: 0.95, 95% CI: 0.81-1.12) with ticagrelor was consistent with the overall cohort and without significant diabetes status-by-treatment interactions. There was no heterogeneity between patients with or without ongoing insulin treatment. Ticagrelor reduced the primary endpoint, all-cause mortality, and stent thrombosis in patients with HbA1c above the median (HR: 0.80, 95% CI: 0.70-0.91; HR: 0.78, 95% CI: 0.65-0.93; and HR: 0.62, 95% CI: 0.39-1.00, respectively) with similar bleeding rates (HR: 0.98, 95% CI: 0.86-1.12). Ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Acute coronary syndromes, Diabetes, Ticagrelor, Clopidogrel, Mortality, Myocardial infarction
in
European Heart Journal
volume
31
issue
24
pages
3006 - 3016
publisher
Oxford University Press
external identifiers
  • wos:000285415900013
  • scopus:78650368771
  • pmid:20802246
ISSN
1522-9645
DOI
10.1093/eurheartj/ehq325
language
English
LU publication?
yes
id
99f13e6a-2dea-44b2-8c09-1ff77f176996 (old id 1831201)
date added to LUP
2016-04-01 14:39:05
date last changed
2022-04-06 19:45:44
@article{99f13e6a-2dea-44b2-8c09-1ff77f176996,
  abstract     = {{Patients with diabetes mellitus (DM) have high platelet reactivity and are at increased risk of ischaemic events and bleeding post-acute coronary syndromes (ACS). In the PLATelet inhibition and patient Outcomes (PLATO) trial, ticagrelor reduced the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke, but with similar rates of major bleeding compared with clopidogrel. We aimed to investigate the outcome with ticagrelor vs. clopidogrel in patients with DM or poor glycaemic control. We analysed patients with pre-existing DM (n = 4662), including 1036 patients on insulin, those without DM (n = 13 951), and subgroups based on admission levels of haemoglobin A1c (HbA1c; n = 15 150). In patients with DM, the reduction in the primary composite endpoint (HR: 0.88, 95% CI: 0.76-1.03), all-cause mortality (HR: 0.82, 95% CI: 0.66-1.01), and stent thrombosis (HR: 0.65, 95% CI: 0.36-1.17) with no increase in major bleeding (HR: 0.95, 95% CI: 0.81-1.12) with ticagrelor was consistent with the overall cohort and without significant diabetes status-by-treatment interactions. There was no heterogeneity between patients with or without ongoing insulin treatment. Ticagrelor reduced the primary endpoint, all-cause mortality, and stent thrombosis in patients with HbA1c above the median (HR: 0.80, 95% CI: 0.70-0.91; HR: 0.78, 95% CI: 0.65-0.93; and HR: 0.62, 95% CI: 0.39-1.00, respectively) with similar bleeding rates (HR: 0.98, 95% CI: 0.86-1.12). Ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events.}},
  author       = {{James, Stefan and Angiolillo, Dominick J. and Cornel, Jan H. and Erlinge, David and Husted, Steen and Kontny, Frederic and Maya, Juan and Nicolau, Jose C. and Spinar, Jindrich and Storey, Robert F. and Stevens, Susanna R. and Wallentin, Lars}},
  issn         = {{1522-9645}},
  keywords     = {{Acute coronary syndromes; Diabetes; Ticagrelor; Clopidogrel; Mortality; Myocardial infarction}},
  language     = {{eng}},
  number       = {{24}},
  pages        = {{3006--3016}},
  publisher    = {{Oxford University Press}},
  series       = {{European Heart Journal}},
  title        = {{Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial}},
  url          = {{http://dx.doi.org/10.1093/eurheartj/ehq325}},
  doi          = {{10.1093/eurheartj/ehq325}},
  volume       = {{31}},
  year         = {{2010}},
}